Status:
NOT_YET_RECRUITING
Taiwanese Anaplastic Thyroid Cancer Registry
Lead Sponsor:
National Health Research Institutes, Taiwan
Conditions:
Thyroid Carcinoma, Anaplastic
Eligibility:
All Genders
18+ years
Brief Summary
Primary treatment strategies for ATC have included surgical resection combined with radiotherapy, chemotherapy, or concurrent chemoradiation therapy. Despite these aggressive approaches, disease recur...
Detailed Description
Thyroid cancers are pathologically classified into differentiated thyroid cancer (DTC),medullary (MTC) and anaplastic carcinoma (ATC). ATC accounts for approximately 1% of thyroid cancer cases in Taiw...
Eligibility Criteria
Inclusion
- Pathologically or cytologically confirmed ATC and diagnosed after 2015.
- Capable of understanding and complying with the protocol requirements and signed informed consent. The dead patient can be enrolled without signed informed consent and they were dead before 2025.6.30.
Exclusion
- Inability and unwillingness to give informed consent except dead patient.
- Patients refuse for collection of clinical data and follow up.
Key Trial Info
Start Date :
September 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2035
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07138261
Start Date
September 1 2025
End Date
December 30 2035
Last Update
August 22 2025
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Taipei Veterans General Hospital
Taipei, Taiwan/Taipei, Taiwan
2
Kaohsiung Medical University
Kaohsiung City, Taiwan
3
National Taiwan University Hospital ,NTUH Hsin-Chu Branch
Sindian City, Taiwan
4
China Medical University Hospital
Taichung, Taiwan